Balchem Co. (NASDAQ:BCPC) to Post Q2 2025 Earnings of $1.04 Per Share, HC Wainwright Forecasts

Balchem Co. (NASDAQ:BCPC) – Equities research analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for Balchem in a research note issued on Monday, May 6th. HC Wainwright analyst R. Selvaraju expects that the basic materials company will earn $1.04 per share for the quarter. HC Wainwright has a “Buy” rating and a $170.00 price target on the stock. The consensus estimate for Balchem’s current full-year earnings is $4.10 per share. HC Wainwright also issued estimates for Balchem’s Q4 2025 earnings at $1.12 EPS.

Separately, StockNews.com downgraded shares of Balchem from a “buy” rating to a “hold” rating in a report on Thursday, April 25th.

Balchem Stock Up 1.4 %

Shares of NASDAQ:BCPC opened at $155.48 on Wednesday. The firm has a fifty day moving average price of $151.00 and a two-hundred day moving average price of $141.21. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.61 and a quick ratio of 1.72. Balchem has a one year low of $110.74 and a one year high of $159.52. The company has a market cap of $5.04 billion, a price-to-earnings ratio of 43.92, a PEG ratio of 3.33 and a beta of 0.72.

Balchem (NASDAQ:BCPC) last announced its quarterly earnings results on Friday, February 16th. The basic materials company reported $0.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.93 by $0.02. Balchem had a net margin of 12.35% and a return on equity of 11.03%. The firm had revenue of $228.70 million for the quarter, compared to the consensus estimate of $234.66 million. During the same period in the prior year, the firm posted $0.66 earnings per share. The company’s revenue for the quarter was down 1.6% on a year-over-year basis.

Insider Buying and Selling at Balchem

In other news, SVP Michael Robert Sestrick sold 11,100 shares of the firm’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $153.21, for a total transaction of $1,700,631.00. Following the sale, the senior vice president now owns 6,736 shares in the company, valued at approximately $1,032,022.56. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, CEO Theodore L. Harris sold 34,350 shares of Balchem stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $154.29, for a total value of $5,299,861.50. Following the transaction, the chief executive officer now owns 66,412 shares in the company, valued at approximately $10,246,707.48. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Michael Robert Sestrick sold 11,100 shares of Balchem stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $153.21, for a total transaction of $1,700,631.00. Following the completion of the transaction, the senior vice president now owns 6,736 shares in the company, valued at approximately $1,032,022.56. The disclosure for this sale can be found here. Insiders sold a total of 76,630 shares of company stock valued at $11,843,249 in the last three months. Company insiders own 1.77% of the company’s stock.

Hedge Funds Weigh In On Balchem

A number of large investors have recently added to or reduced their stakes in the business. Sei Investments Co. increased its position in shares of Balchem by 4.1% in the first quarter. Sei Investments Co. now owns 127,822 shares of the basic materials company’s stock valued at $19,805,000 after acquiring an additional 5,001 shares during the period. Illinois Municipal Retirement Fund increased its position in shares of Balchem by 2.5% in the first quarter. Illinois Municipal Retirement Fund now owns 18,352 shares of the basic materials company’s stock valued at $2,844,000 after acquiring an additional 442 shares during the period. Quantbot Technologies LP purchased a new position in shares of Balchem in the first quarter valued at about $495,000. Envestnet Portfolio Solutions Inc. increased its position in shares of Balchem by 2.8% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 3,867 shares of the basic materials company’s stock valued at $599,000 after acquiring an additional 104 shares during the period. Finally, Texas Permanent School Fund Corp increased its position in shares of Balchem by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 28,217 shares of the basic materials company’s stock valued at $4,372,000 after acquiring an additional 365 shares during the period. Hedge funds and other institutional investors own 87.91% of the company’s stock.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.